ISK Ltd has successfully completed a Phase I clinical trial with Nerofe, a promising new treatment for patients with progressive cancer. The trial demonstrated that Nerofe is safe for human use, with no toxic effects observed. Furthermore, Nerofe remains stable in human blood.

Nerofe’s Triple Action Mechanism

Unlike conventional anti-cancer drugs that target a single biological process supporting cancer progression, Nerofe is the first highly safe anti-cancer agent that inhibits all three key biological processes:

  1. Anti-angiogenic effect: Nerofe induces a strong anti-angiogenic effect, inhibiting the formation of blood vessels around the tumor.
  2. Activation of anti-cancer immune response: Nerofe activates the body’s immune response against cancer cells.
  3. Inhibition of cancer cell proliferation: In vitro experiments have shown that Nerofe has a direct and strong inhibitory effect on cancer cell proliferation.

Predictive Marker for Treatment Success

We have developed a novel marker that can predict the success of treatment with Nerofe. Patients whose tumor biopsies tested positive for this marker remained in the trial for six months or longer, maintaining a stable disease state.

Our Focus

ISK Ltd is primarily focused on treating patients with Acute Myeloid Leukemia (AML), pancreatic cancer, and triple-negative (TN) breast cancer.

Nerofe® triple-action:
  • Cytotoxic for cancer and inflamed cells.
  • Activates immune system response.
  • Inhibits angiogenesis
Nerofe causes ER stress to different type of cells

Nerofe causes ER stress to different type of cells through ST2 receptor


Ohana J, Sandler U,2, Kass G, Stemmer SM, Devary Y. – dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of Golgi function.